Publicaciones en colaboración con investigadores/as de Hospital Universitario Marqués de Valdecilla (44)

2024

  1. Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial

    The Lancet Infectious Diseases, Vol. 24, Núm. 4, pp. 375-385

  2. Two episodes of bacteremia of zoonotic origin caused by different Streptococcus canis isolates in the same patient within a time span of 1 year

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 43, Núm. 2, pp. 383-387

2023

  1. Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 36, Núm. 3, pp. 302-309

  2. Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

    International Journal of Infectious Diseases, Vol. 137, pp. 134-143

2022

  1. Detection of azole resistance in Aspergillus fumigatus complex isolates using MALDI-TOF mass spectrometry

    Clinical Microbiology and Infection, Vol. 28, Núm. 2, pp. 260-266

  2. Outpatient Parenteral Antibiotic Treatment vs Hospitalization for Infective Endocarditis: Validation of the OPAT-GAMES Criteria

    Open Forum Infectious Diseases, Vol. 9, Núm. 9

  3. Study protocol for a randomized clinical trial to assess 7 versus 14-days of treatment for Pseudomonas aeruginosa bloodstream infections (SHORTEN-2 trial)

    PLoS ONE, Vol. 17, Núm. 12 December

2021

  1. Azole and amphotericin B MIC values against aspergillus fumigatus: High agreement between spectrophotometric and visual readings using the EUCAST EDef 9.3.2 procedure

    Antimicrobial Agents and Chemotherapy, Vol. 65, Núm. 1

  2. Azole resistance survey on clinical Aspergillus fumigatus isolates in Spain

    Clinical Microbiology and Infection, Vol. 27, Núm. 8, pp. 1170.e1-1170.e7

  3. Clinical Features and Outcomes of Streptococcus anginosus Group Infective Endocarditis: A Multicenter Matched Cohort Study

    Open Forum Infectious Diseases, Vol. 8, Núm. 6

  4. Evaluation of Vitek-MS™ and Microflex LT™ commercial systems for identification of Acinetobacter calcoaceticus–baumannii complex

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 39, Núm. 1, pp. 9-13

  5. Invasive aspergillosis in solid organ transplantation: Diagnostic challenges and differences in outcome in a Spanish national cohort (Diaspersot study)

    Mycoses, Vol. 64, Núm. 11, pp. 1334-1345

  6. Mural Endocarditis: The GAMES Registry Series and Review of the Literature

    Infectious Diseases and Therapy, Vol. 10, Núm. 4, pp. 2749-2764

  7. Prevalence of Colorectal Neoplasms Among Patients With Enterococcus faecalis Endocarditis in the GAMES Cohort (2008–2017)

    Mayo Clinic Proceedings, Vol. 96, Núm. 1, pp. 132-146

  8. Propensity score and desirability of outcome ranking analysis of ertapenem for treatment of nonsevere bacteremic urinary tract infections due to extended-spectrum-beta-lactamase-producing enterobacterales in kidney transplant recipients

    Antimicrobial Agents and Chemotherapy, Vol. 65, Núm. 11

  9. The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant

    Nature Genetics, Vol. 53, Núm. 10, pp. 1405-1414

2020

  1. A Contemporary Picture of Enterococcal Endocarditis

    Journal of the American College of Cardiology, Vol. 75, Núm. 5, pp. 482-494

  2. Clinical predictive model of multidrug resistance in neutropenic cancer patients with bloodstream infection due to Pseudomonas aeruginosa

    Antimicrobial Agents and Chemotherapy, Vol. 64, Núm. 4

2019

  1. Role of age and comorbidities in mortality of patients with infective endocarditis

    European Journal of Internal Medicine, Vol. 64, pp. 63-71

2018

  1. Erratum for del Barrio-Tofiño et al., "Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain"

    Antimicrobial agents and chemotherapy